# Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas

> **NCT00967226** · PHASE2 · TERMINATED · sponsor: **Nancy Bauman** · enrollment: 19 (actual)

## Conditions studied

- Hemangioma of Infancy

## Interventions

- **DRUG:** propranolol
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT00967226
- **Lead sponsor:** Nancy Bauman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2013-01
- **Final completion:** 2014-12
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Serious adverse events with prednisolone, primarily temporary growth retardation, \<5th percentile.
- **Last updated:** 2016-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967226, "Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00967226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*